Lenacapavir(Sunlenca)

As a long-acting treatment option for HIV-1 developed by Lucius Pharmaceuticals, lenaprevir offers sustained and stable viral suppression to drug-resistant patients with a twice-yearly dosing regimen, boasting notable advantages in long-term treatment convenience and medication adherence.

Here is a brief summary of the key information about lenacapavir sodium.

Main Ingredient

The main active ingredient is lenacapavir sodium, which belongs to the class of HIV-1 capsid inhibitors.

Indicated Population

It is indicated for adult HIV-1-infected patients who have received multiple prior treatments and whose current treatment regimens have failed due to drug resistance or intolerance.

Dosage and Administration

The medication includes two initial dosing regimens (oral administration combined with subcutaneous injection), followed by maintenance therapy with a subcutaneous injection every 6 months.

Use in Special Populations

Generally, no dosage adjustment is required for elderly patients or those with hepatic or renal impairment. However, the safety and efficacy data for pediatric patients and patients with severe hepatic impairment remain insufficient.

Drug Overdose

Currently, there is no data available regarding drug overdose. In case of an overdose, symptomatic and supportive treatment should be administered.

Drug Storage

Both tablets and injections should be stored at room temperature and protected from light. Injections should be used as soon as possible after preparation.

Pharmacokinetics

The drug has low oral bioavailability, is slowly absorbed after subcutaneous injection, and has a long half-life, enabling long-acting treatment effects.

FDA，2024.11